Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Lin G, Pankuch GA, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2010 May;54(5):2201-5. doi: 10.1128/AAC.01143-09. Epub 2010 Feb 16.

2.

Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.

Lin G, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2010 May;54(5):2258-61. doi: 10.1128/AAC.01350-09. Epub 2010 Feb 9.

3.

Comparative antipneumococcal activities of sulopenem and other drugs.

Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Jun;53(6):2239-47. doi: 10.1128/AAC.01531-08. Epub 2009 Mar 23.

4.

Antianaerobic activity of sulopenem compared to six other agents.

Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2009 May;53(5):2163-70. doi: 10.1128/AAC.01557-08. Epub 2009 Feb 17.

5.

Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.

Clark C, Ednie LM, Lin G, Smith K, Kosowska-Shick K, McGhee P, Dewasse B, Beachel L, Caspers P, Gaucher B, Mert G, Shapiro S, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Apr;53(4):1353-61. doi: 10.1128/AAC.01619-08. Epub 2009 Feb 2.

6.

Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Kosowska-Shick K, Ednie LM, McGhee P, Smith K, Todd CD, Wehler A, Appelbaum PC.

Antimicrob Agents Chemother. 2008 Dec;52(12):4510-3. doi: 10.1128/AAC.01073-08. Epub 2008 Oct 6.

7.

Antistreptococcal activity of AR-709 compared to that of other agents.

Smith K, Ednie LM, Appelbaum PC, Hawser S, Lociuro S.

Antimicrob Agents Chemother. 2008 Jun;52(6):2279-82. doi: 10.1128/AAC.01620-07. Epub 2008 Mar 24.

8.

Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.

Credito KL, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2008 Jan;52(1):365-73. Epub 2007 Oct 15.

9.

Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.

Clark CL, Kosowska-Shick K, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2007 Nov;51(11):4196-201. Epub 2007 Sep 17.

10.

Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.

Kosowska-Shick K, Smith K, Bogdanovich T, Ednie LM, Jones RN, Appelbaum PC.

Antimicrob Agents Chemother. 2006 Dec;50(12):4191-4. Epub 2006 Oct 16.

11.

Antipneumococcal activity of dalbavancin compared to other agents.

Lin G, Smith K, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2005 Dec;49(12):5182-4.

12.

Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC.

Antimicrob Agents Chemother. 2005 Oct;49(10):4210-9.

13.

Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Bogdanovich T, Esel D, Kelly LM, Bozdogan B, Credito K, Lin G, Smith K, Ednie LM, Hoellman DB, Appelbaum PC.

Antimicrob Agents Chemother. 2005 Aug;49(8):3325-33.

14.

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Lin G, Credito K, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2005 Feb;49(2):770-2.

15.

Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.

Matic V, Kosowska K, Bozdogan B, Kelly LM, Smith K, Ednie LM, Lin G, Credito KL, Clark CL, McGhee P, Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2004 Nov;48(11):4103-12.

16.

Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Credito K, Lin G, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2004 Oct;48(10):4033-6.

17.

Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Ednie LM, Pankuch G, Appelbaum PC.

Antimicrob Agents Chemother. 2004 Oct;48(10):4027-32.

18.

Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis.

Syrogiannopoulos GA, Bozdogan B, Grivea IN, Ednie LM, Kritikou DI, Katopodis GD, Beratis NG, Applebaum PC; Hellenic Antibiotic-Resistant Respiratory Pathogens Study Group.

Pediatr Infect Dis J. 2004 Sep;23(9):857-65.

PMID:
15361727
19.

Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A).

Syrogiannopoulos GA, Grivea IN, Ednie LM, Bozdogan B, Katopodis GD, Beratis NG, Davies TA, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Aug;47(8):2699-702.

20.

Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.

Hoellman DB, Lin G, Ednie LM, Rattan A, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Mar;47(3):1148-50.

21.

Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.

Ednie LM, Rattan A, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Mar;47(3):1143-7.

22.

Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.

Ednie LM, Jacobs MR, Appelbaum PC.

J Antimicrob Chemother. 2002 Jul;50(1):101-5.

PMID:
12096013
23.

Activity of cefditoren against respiratory pathogens.

Clark CL, Nagai K, Dewasse BE, Pankuch GA, Ednie LM, Jacobs MR, Appelbaum PC.

J Antimicrob Chemother. 2002 Jul;50(1):33-41.

PMID:
12096004
24.

In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.

Hoellman DB, Kelly LM, Credito K, Anthony L, Ednie LM, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2002 Jan;46(1):220-4.

26.

Antipneumococcal activity of ABT-773 compared to those of 10 other agents.

Davies TA, Ednie LM, Hoellman DM, Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2000 Jul;44(7):1894-9.

27.

Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.

Ednie LM, Credito KL, Khantipong M, Jacobs MR, Appelbaum PC.

J Antimicrob Chemother. 2000 May;45(5):633-8.

PMID:
10797085
28.
29.

Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, Bajaksouzian S, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2000 Mar;44(3):633-9.

30.

Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.

Credito KL, Ednie LM, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1999 Aug;43(8):2027-31.

31.

Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

Ednie LM, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1998 Sep;42(9):2459-62.

32.

Comparative activities of clinafloxacin against gram-positive and -negative bacteria.

Ednie LM, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1998 May;42(5):1269-73.

34.

Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).

Ednie LM, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1997 Sep;41(9):2019-22.

35.
37.

Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.

Fasola E, Spangler SK, Ednie LM, Jacobs MR, Bajaksouzian S, Appelbaum PC.

Antimicrob Agents Chemother. 1996 Nov;40(11):2661-3.

38.

Supplemental Content

Loading ...
Support Center